Advisory Board and Editors Immunology
John J. Mekalanos
John Mekalanos is the Adele H. Lehman Professor of Microbiology and Molecular Genetics at Harvard Medical School. He has served as Chair of the Microbiology and Molecular Genetics Department since 1996, and he is a member of the National Academy of Sciences and the American Academy of Microbiology.
Dr. Mekalanos has received amongst other honors the Eli Lilly Award and American Association for the Advancement of Science Newcomb Cleveland Prize for the Outstanding Paper of 1993 Published in Science (259:686-688, 1993). He has been a member of the FDA Advisory Committee on Vaccines and Related Biologics, and has consulted for numerous other governmental and private agencies, including NIH, DOD, the World Health Organization, The International Vaccine Institute, the National Academy of Sciences, Massachusetts Public Health Biological Laboratories, and the US-Japan Cooperative Medical Science Program. Dr. Mekalanos has been an active consultant in the pharmaceutical industry for companies including SmithKline, Merck, and Vicuron, and he was a co-founder of three biotechnology firms (Virus Research Institute, PharmAthene and most recently, Matrivax). He received the Sanofi-Institut Pasteur 2012 Award. He and his group have published over 200 research articles, and he has supervised more than 50 trainees in his lab during his career thus far.
Daniel J Moore
Dr. Moore completed his undergraduate training at Harvard University where he also studied at the MGH Transplantation Biology Research Center (TBRC). He continued his focus in transplantation immunology and autoimmune disease during studies in the MSTP program at the University of Pennsylvania. He subsequently completed his training in pediatrics and pediatric endocrinology at Vanderbilt University Medical Center. His laboratory focus is on the restoration of immune regulation in individuals with autoimmune disease. He pursues this effort through studies on the cellular and molecular biology of effector and regulatory lymphocytes and their responses to tolerance-inducing immune therapies.
Héctor Manuel Mora-Montes
In 2010, I established the Laboratory of Fungal Glycobiology at Universidad de Guanajuato, Mexico, with the main goal to understand the synthesis mechanisms of the fungal cell wall and the interaction of medically relevant fungal pathogens with the host. This laboratory is characterized by its facilities to perform chemical, immunological, genetic, molecular, and cellular analyses of human fungal pathogens. Therefore, it is among a handful of research facilities within Mexico and Latin America offering a multidisciplinary and integral approach to understand the host-fungus interaction. Our group has a solid international reputation in the molecular and immunological studies of organisms belonging to the genus Candida and Sporothrix.
Karen L. Mossman
Professor of Pathology and Molecular Medicine and member of the Institute of Infectious Disease Research and McMaster Immunology Research Centre at McMaster University. Associate Editor of PLOS Pathogens and PLOS ONE and Editorial Board Member of Journal of Virology. Recipient of the 2006 Christina Fleischmann Award from the International Society for Interferon and Cytokine Research.
James J. Mulé
- Executive Vice President and Associate Center Director for Translational Research
- Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment
- Co-Director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center.
Dr. Mulé is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors. He has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy; and he has been an NCI-NIH investigator continuously for nearly 20 years.
Dr. Mulé serves on the advisory board of M2Gen, a wholly-owned subsidiary of the Moffitt Cancer Center in the area of personalized medicine in oncology, which he helped to establish; the Board of Directors of Medicine in Need, Cambridge, MA (a non-profit spin-out of Harvard University, and selected as a 2011 Technology Pioneer by the World Economic Forum); and the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A, clinical), remaining a long-standing special government employee to the FDA and the NCI; the scientific/medical advisory boards of several private and public companies where he also served as a consultant; and he chaired the FDA’s CBER Cellular, Tissue, and Gene Therapy Advisory Committee.
Shobana Navaneethabalakrishnan
I received my PhD in Reproductive Endocrinology from University of Madras, India where I studied the molecular mechanism underlying the repression of follicle stimulating hormone receptor and androgen receptor in Sertoli cells of F1 progeny rats with gestational exposure to hexavalent chromium. I have successfully attained inter-laboratory collaboration to study the effect of gestational exposure to excess hexavalent chromium on insulin signaling molecules and glucose homeostasis in F1 progeny rats. Currently, my research focus is to understand the role of gonadal macrophage polarization in reproductive dysfunction associated with hypertension in both men and women.
Sarwat Naz
Dr. Naz obtained her PhD degree in 2013 from Indian Institute of Science, India. She then moved to USA to conduct her postdoctoral training. She is currently a Scientist at National Cancer Institute at NIH, USA where she conducts clinical and translational research in the field of cancer. Her primary research focus is identification of means to modify the radiation response of tumors without causing damage to surrounding normal tissues. Her research utilizes testing novel agents that target specific molecular pathways important in radiation responses to probe the radio sensitivity of cells/tissues. In her current role at NCI she manages translational research initiatives involving radiation modification, the influence of tumor microenvironment on cancer immunotherapy, and novel molecular imaging platforms to assess tissue metabolism.
Barbara Nowak
Barbara is Professor at the University of Tasmania (UTAS), where she leads Aquatic Animal Health research group. Barbara has her PhD from Sydney University and has been working at UTAS since 1991. Her research interests focus on various aspects of fish health, such as fish parasitology, fish immunology and fish pathology. Barbara has published over 200 papers and supervised more than 30 PhD students. She has received awards for her research and supervision of PhD students.
Luke O'Neill
Chair of Biochemistry at Trinity College Dublin & Academic Director of the Trinity Biomedical Sciences Institute. Awards include the Royal Irish Academy Medal for Biochemistry, The Irish Society for Immunology medal, the Royal Dublin Society/Irish Times Boyle medal for Scientific Excellence & the Science Foundation Ireland Researcher of the Year Award. Co-founder and director of Opsona Therapeutics. In 2008 he was appointed Chair of the Immunity & Infection panel of the European Research Council
Masahiro Ono
Dr Masahiro Ono was originally trained as a dermatologist, and later specialised in immunology. He obtained his PhD in 2006 by a study on regulatory T cells (Treg), and later identified the interaction of the Treg-specific transcription factor Foxp3 and the transcription factor Runx1. In 2009, he obtained a HFSP Fellowship, and joined University College London (UCL), when he established a new genomic analysis tool using a multidimensional method, Canonical Correspondence Analysis (CCA). In 2012, he was awarded a BBSRC David Phillips Fellowship, and established his lab in UCL. In 2015, he moved in the Department of Life Sciences, Imperial, and was appointed as Senior Lecturer in 2018.
Recently, the Ono group has established a novel tool for analysing temporal dynamics of cellular differentiation and activation in vivo, Timer-of-Cell-Kinetics-and-Activity (Tocky とき), and his group is using this tool to investigate mechanisms underlying T cell differentiation and T cell-mediated immune response.
Anup Singh Pathania
Dr. Anup Pathania is a Research Instructor at the University of Nebraska Medical Center (UNMC).
His research interests include non-coding RNAs in cancer, pharmacology and immunology. He is currently investigating the underlying mechanisms in the stabilization of PD-L1 by exosmic non-coding RNAs in neuroblastoma cells within the tumor microenvironment.
George N. Pavlakis
MD, University of Athens, Greece
PhD, Syracuse University, NY
Chief of the Human Retrovirus Section of the National Cancer Institute, USA
Interests: HIV pathogenesis, Molecular Biology, gene regulation, Biotechnology, protein engineering, cytokines, Immunotherapy, Vaccines, Nucleic acid vaccines, gene therapy